The management of transaminitis in patients receiving idelalisib
Treatment-associated atrial fibrillation: ibrutinib-specific or class-specific?
Can we afford to have CLL patients on a therapy for the rest of their lives?
John Gribben et al.
Side effects of idelalisib in CLL and how to manage them
The goals and work of the European Research Initiative on CLL (ERIC)